CABLIVI ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 64 | 血栓性血小板減少性紫斑病 | 2 |
64. 血栓性血小板減少性紫斑病
臨床試験数 : 86 / 薬物数 : 81 - (DrugBank : 20) / 標的遺伝子数 : 16 - 標的パスウェイ数 : 63
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04985318 (ClinicalTrials.gov) | March 25, 2021 | 21/7/2021 | Retrospective Analysis of the Efficiency of Caplacizumab in the Treatment of aTTP | Retrospective Analysis of the Efficiency of Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura (aTTP)- REACT-2020 | Acquired Thrombotic Thrombocytopenic Purpura | Drug: Cablivi® | University of Cologne | NULL | Recruiting | 18 Years | N/A | All | 350 | Germany | |
| 2 | EUCTR2020-005288-30-FR (EUCTR) | 28/12/2020 | 06/11/2020 | Efficacy of a personalized caplacizumab regimen based on ADAMTS-13 activity monitoring in adult acquired thrombotic thrombocytopenic purpura: A phase II, multicenter non-inferiority single-arm study | Efficacy of a personalized caplacizumab regimen based on ADAMTS-13 activity monitoring in adult acquired thrombotic thrombocytopenic purpura: A phase II, multicenter non-inferiority single-arm study - CAPLAVIE | acquired thrombotic thrombocytopenic purpura MedDRA version: 20.0;Level: PT;Classification code 10043648;Term: Thrombotic thrombocytopenic purpura;System Organ Class: 10005329 - Blood and lymphatic system disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Trade Name: CABLIVI | CHU de Rouen | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 125 | Phase 2 | France |